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Endothelial cell dysfunction is a term which implies the dysregulation of normal endothelial cell functions, including impair-
ment of the barrier functions, control of vascular tone, disturbance of proliferative and migratory capacity of endothelial cells, 
as well as control of leukocyte trafficking. Endothelial dysfunction is an early step in vascular inflammatory diseases such as 
atherosclerosis, diabetic vascular complications, sepsis-induced or severe virus infection-induced organ injuries. The expres-
sions of inflammatory cytokines and vascular adhesion molecules induced by various stimuli, such as modified lipids, smoking, 
advanced glycation end products and bacteria toxin, significantly contribute to the development of endothelial dysfunction. 
The transcriptional regulation of inflammatory cytokines and vascular adhesion molecules has been well-studied. However, the 
regulation of those gene expressions at post-transcriptional level is emerging. RNA-binding proteins have emerged as critical 
regulators of gene expression acting predominantly at the post-transcriptional level in microRNA-dependent or independent 
manners. This review summarizes the latest insights into the roles of RNA-binding proteins in controlling vascular endothelial 
cell functions and their contribution to the pathogenesis of vascular inflammatory diseases.  
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The endothelium is the monolayer of endothelial cells (ECs) 
lining the lumen of blood vessels in every organ system. 
These cells form a protective barrier between all tissues and 
the circulating blood. Normal EC function is critical for all 
aspects of vascular homeostasis (i.e., control of blood vessel 
development, growth and differentiation; control of leuko-
cyte trafficking; control of vascular tone; control of vascular 
barrier; control of platelet function, coagulation and fibri-
nolysis) [13]. EC dysfunction disrupts the balance between 
vasoconstriction and vasodilation and initiates a number of 
events that trigger EC activation and predispose the vessel 
wall to increased endothelial permeability, leukocyte ad-
herence, endothelial proliferation, pro-oxidation and 
thrombosis. Endothelial dysfunction has been implicated in 
several diseases including atherosclerosis, diabetes, tumor 
metastasis, sepsis and severe virus infectious diseases [46]. 
Importantly, the expressions of inflammatory cytokines and 
vascular adhesion molecules are significantly involved in 
the processes of EC activation, which is regulated by the 
transcriptional regulation programs, as well as post-   
transcriptional and post-translational modifications that fi-
ne-tune this response [7,8]. microRNA (miRNA) is a key 
transcriptional regulator. In this regard, miRNAs have 
emerged as critical regulators of gene expression, acting 
predominantly at the post-transcriptional level [911]. 
RNA-binding proteins have also emerged as critical regula-
tors of gene expression at the post-transcriptional level. 
They can act in a miRNA-dependent or independent way. 
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Since the functions of miRNAs in vascular endothelial dys-
function have been comprehensively reviewed elsewhere 
[1215], in the present review we summarize the latest in-
sights into the roles of RNA-binding proteins in controlling 
vascular endothelial cell functions and their contributions to 
the pathogenesis of vascular inflammatory diseases.  
1  Endothelial dysfunction in human diseases 
The endothelium maintains normal vascular homeostasis 
with no or little expression of proinflammatory factors un-
der normal homeostatic conditions. However, both tradi-
tional and novel cardiovascular risk factors including 
smoking, aging, hypercholesterolemia, hypertension, hy-
perglycemia, and a family history of premature atheroscle-
rotic disease are associated with alteration in endothelial 
function [46]. In addition, infections with bacteria and 
viruses also impair the blood-tissue barrier and result in 
tissue/organ injuries [16,17]. This results in a chronic or 
acute inflammatory process accompanied by loss of an-
tithrombotic factors and an increase in proinflammatory 
cytokines and prothrombotic products, in addition to ab-
normal vasoreactivity, therefore elevating risk of cardio-
vascular events and organ injuries. 
1.1  Endothelial dysfunction and atherosclerosis 
Atherosclerosis is characterized by the thickening of the 
arterial wall and is the primary cause of coronary artery 
disease and cerebrovascular disease, two of the most com-
mon causes of illness and death worldwide [18]. A crucial 
step in atherogenesis is the arterial recruitment of inflam-
matory cells from the circulation and their trans-endothelial 
migration into the sub-endothelial space of large arteries 
where they differentiate into macrophages and become 
functionally active. The endothelial activation is the first 
step in the development of atherosclerosis [19]. In response 
to inflammatory stimuli, such as tumor necrosis factor α 
(TNFα), interleukin 1β (IL-1β), and interferon gamma, ECs 
undergo inflammatory activation, resulting in an increased 
surface expression of cell adhesion molecules, such as vas-
cular cell adhesion molecule (VCAM)-1, intercellular adhe-
sion molecule (ICAM)-1, and E-selectin, which contributes 
to the recruitment of inflammatory cells to arterial wall and 
their transmigration across the wall. The activated ECs also 
release cytokines and chemokines such as monocyte chem-
otactic protein 1 (MCP-1), which is a potent inducer for 
monocyte attachment to ECs and migration into subendo-
thelial space. Endothelial activation represents a switch 
from a quiescent phenotype toward a proinflammatory and 
prothrombotic phenotype. Indeed, most cardiovascular risk 
factors induce the expression of chemokines, cytokines, and 
adhesion molecules designed to interact with leukocytes and 
platelets in endothelium [20,21]. The molecular regulation 
of the gene expression program in endothelium is an inten-
sively studied area.  
1.2  Endothelial dysfunction and metabolic syndromes 
Metabolic syndrome is a cluster of metabolic abnormalities 
that includes visceral obesity, dyslipidemia, hypertension, 
and impairment of glucose metabolism, which has been 
related to both endothelial dysfunction and increased risk 
for cardiovascular diseases and type 2 diabetes. Insulin re-
sistance has been recognized as a common cause for clus-
tering of these risk factors, whereas endothelial dysfunction 
may contribute to the progression of metabolic syndrome 
and the development of adverse outcome [22,23]. A grow-
ing body of evidence suggests that endothelial dysfunction 
may precede the development of insulin resistance or fur-
ther promote the occurrence of manifest diabetic mellitus 
[24]. For example, eNOS-deficiency not only results in en-
dothelial dysfunction, but also causes the development of 
insulin resistance and metabolic abnormalities, similar to 
those observed in diabetic mellitus [25]. The prospective 
investigations have also linked the increased levels of cir-
culating markers of endothelial damage (i.e., plasminogen 
activator inhibitor-1 and von Willebrand factor) to the risk 
of incident diabetic mellitus [26]. 
1.3  Endothelial dysfunction and septic shock 
Septic shock poses a serious public health problem world-
wide with an overall mortality rate of 30%. Now it is recog-
nized that a major contributor to septic morbidity and mor-
tality is the breakdown in the function of the blood/tissue 
barrier due to intravascular or extra-vascular infections 
[27,28]. This breakdown is caused by a cascade of inflam-
matory events resulting in severe endothelial dysfunction 
which leads to systemic vascular leakage and irreversible 
multi-organ failure. Blood and vascular systems that re-
spond to sepsis-associated microbial virulence factors en-
compass innate and adaptive immune cells, platelets, and 
the plasma proteins that represent antibody, complement, 
coagulation and fibrinolysis networks. These blood systems 
are enclosed by the enormous surface of the microvascular 
endothelium forming organ-specific vascular beds. It is vital 
that the blood/tissue barrier formed by this microvascular 
endothelium and the adjoining structures maintain their 
structural and functional integrity in order to support normal 
physiological functions of key organs. During sepsis-  
causing infections, the vasculature is profoundly altered by 
the combination of microbial virulence factors and proin-
flammatory mediators released from activated blood cells 
that gain access to surrounding tissue by crossing the leaky 
endothelial boundary. Severe endothelial dysfunction then 
results from the loss of homeostatic function of the micro-
vascular endothelium and contributes to hypoxic injury of 
multiple organs. It is therefore clear that breakdown of the 
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blood/endothelial tissue barrier is one of the major contrib-
utors to sepsis morbidity and mortality. By preventing vas-
cular leakage through reinforcement of the endothelial bar-
rier, it is likely that mortality from sepsis can be reduced 
[30,31].  
1.4  Endothelial dysfunction and severe virus infectious 
diseases 
It is increasingly evident that endothelial dysfunction also 
contributes to the pathogenesis of a variety of potentially 
serious virus infectious diseases and syndromes, including 
dengue hemorrhagic fever, severe acute respiratory syn-
drome (SARS) and H1N1 influenza [3234]. The develop-
ment of severe virus infection-caused organ injury, for ex-
ample, acute lung injury, has been attributed to a heightened 
innate immune response. Recent evidence suggests that en-
dothelial activation, loss of barrier function, and consequent 
microvascular leak may also serve important mechanistic 
roles in the pathogenesis of severe virus infection. Shock 
syndrome is a dangerous complication of dengue infection 
and is associated with high mortality [35]. Severe dengue 
occurs as a result of secondary infection with a different 
virus serotype. Increased vascular permeability, together 
with myocardial dysfunction and dehydration, contribute to 
the development of shock, with resultant multi-organ failure 
[36]. The pathogenesis of shock in dengue is complex. It is 
known that endothelial dysfunction induced by cytokines 
and chemical mediators occurs. Understanding the regula-
tory mechanisms of endothelial dysfunction under severe 
virus infection may help to develop novel therapeutic strat-
egies to cure these severe diseases. 
2  Post-transcriptional gene regulation  
Gene expression is a highly regulated process that begins 
with transcriptional initiation and ends with translation of a 
mature mRNA into protein. Between these two points, there 
are a series of events including processing and splicing of 
the pre-mRNA, export of the message from the nucleus to 
the cytoplasm, quality control assessment of the mRNA 
through the pioneer round of translation, message decay and 
stabilization, and translational repression and de-repression 
[37]. All of these events from initiation of transcription by 
transcription factors to the stability of the message to effec-
tive translation of the message are controlled by the pres-
ence of specific nucleotide sequences which are bound by 
specific RNA-binding proteins [38]. As a message is tran-
scribed, proteins bind to form a messenger ribonucleo pro-
tein complex (mRNP) and the composition of the mRNP 
controls all aspects of the life of the mRNA, from 
pre-mRNA processing to mRNA localization to translation 
and degradation. Transitions between these events are ac-
companied by mRNP remodeling and exchange of mRNP 
proteins. Posttranscriptional control of gene expression, 
particularly mRNA stability and translation, allows for rapid 
changes in mRNA levels. Dysregulated mRNA stability and 
translation underlie a number of diseases, directly contrib-
uting to the overexpression of many genes encoding growth 
factors, inflammatory cytokines, and proto-oncogenes. mi-
croRNAs are an important layer that control gene expres-
sion at post-transcriptional level, which has been extensive-
ly reviewed elsewhere [911]. microRNAs need to function 
together with RNA-binding proteins. The role of RNA- 
binding proteins in regulation of gene expression at 
post-transcriptional level has been emerging. 
3  RNA-binding proteins in vascular endothelial 
dysfunction 
3.1  Tristetraprolin 
Tristetraprolin (TTP), also known as Nup475, G0S24, and 
TIS11, is the best known member of a class of proteins 
containing tandem CCCH zinc fingers. It is an mRNA-  
destabilizing protein that binds to AU-rich elements in la-
bile transcripts, such as the mRNA encoding TNF, and 
promotes their deadenylation and degradation [3941]. TTP 
destabilizes mRNA transcripts encoding multiple inflam-
matory modulators, including granulocyte-macrophage 
colony-stimulating factor (GM-CSF), IL-2, IL-6, C-FOS, 
iNOS, cyclooxygenase 2, CCL2, CCL3, CXC-chemokine 
ligand 1 (CXCL1), IFNγ and IL-10 [4247]. As a conse-
quence, TTP-deficient mice exhibit an early-onset, severe 
inflammatory phenotype, with cachexia, erosive arthritis, 
left-sided cardiac valvulitis, myeloid hyperplasia, and au-
toimmunity, which can be prevented by injection of anti- 
TNF antibody, or interbreeding with TNF receptor-deficient 
mice [48,49]. TTP promotes mRNA decay by binding di-
rectly to components of the mRNA decay machinery, in-
cluding the mRNA-decapping enzymes DCP1A and DCP2, 
the deadenylaseCNOT6 (CCR4-NOT transcription complex 
subunit 6), the 5′3′ exoribonuclease 1 (XRN1), exosome 
complex endonuclease PM-SCl75 (also known as RRP45) 
and argonaute 2 (AGO2), an argonaute protein component 
of the RNA-induced silencing complex [5052]. TTP exerts 
its role in miRNA-dependent and independent ways [53]. 
It was observed that TTP-deficient mice also developed 
endothelial dysfunction [54]. TTP mice showed a signifi-
cant reduction of acetylcholine-induced nitric oxide-   
mediated vasorelaxation, which was associated with in-
creased levels of reactive oxygen and nitrogen species. The 
altered reactive oxygen and nitrogen species generation 
correlates with increased expression of NADPH oxidase 2 
resulting from enhanced NADPH oxidase 2 mRNA stability. 
Zhang et al. [55] recently observed that ZFP36 (TTP) is 
expressed in the vascular endothelium of mice with athero-
sclerosis but not in the vascular endothelium of normal mice.  
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Overexpression of TTP inhibited the expression of proin-
flammatory mRNA transcripts in vascular endothelial cells. 
The anti-inflammatory effects of TTP in endothelial cells 
occur via both transcriptional and post-transcriptional 
mechanisms. These studies suggest that enhancing vascular 
TTP expression might reduce vascular inflammation. Dai et 
al. [56] also found that TTP promoted decay of CD36 
mRNA, by which it may inhibit macrophage foam-cell for-
mation. Thus, TTP may function as an important inhibitor 
in the development of atherosclerosis through multiple 
mechanisms.  
Endothelial cells are primary sensors of variations in 
blood oxygen concentrations. They use the hypoxia-   
sensitive stabilization of the hypoxia-inducible factor-1α 
(HIF-1α) transcription factor to engage specific transcrip-
tional programs in response to oxygen changes. It was ob-
served that silencing TTP in endothelial cells reverses hy-
poxia-induced down-regulation of HIF-1α mRNA. In addi-
tion, TTP mediated prolonged hypoxia-induced increase in 
the half-life of luciferase-HIF-1α-3′ UTR reporter transcript, 
suggesting that TTP plays a new role in the control of gene 
expression during the response of endothelial cell to hypox-
ia [57]. Besides the important role of chronic vascular in-
flammation, TTP is also important in regulation of acute 
vascular inflammation. Qiu et al. [58] recently observed that 
myeloid-specific TTP deficiency in mice results in extreme 
lipopolysaccharide sensitivity, with rapid development of 
typical endotoxemia signs and extensive organ damage, and 
elevation of serum TNF levels to 110-fold greater than that 
of the control. It is clear that TTP appears to regulate the 
different steps of mRNA processing and fate including 
transcription, splicing, polyadenylation, translation, and 
degradation. The role of TTP in vascular endothelial dys-
function is emerging. Understanding the intricacies of 
TTP-mediated cytokine mRNA degradation and having 
more detailed knowledge of the mRNAs which are regulat-
ed by TTP will identify potential targets for the develop-
ment of anti-inflammatory drugs. 
3.2  HuR 
HuR is a member of the Drosophila Elav protein family that 
binds mRNA degradation sequences and prevents RNase- 
mediated degradation [59,60]. HuR also binds to ARE in 
inflammatory cytokine mRNAs. In contrast with TTP, HuR 
increases the stability of tumor necrosis factor (TNF), vas-
cular endothelial growth factor (VEGF), cyclooxygenase 2 
(COX-2) and toll-like receptor 4 (TLR4) mRNAs [6163]. 
HuR and TTP are both RNA-binding proteins, which are 
characterized as binding to the AU-rich elements (AREs) in 
the 3′-untranslated region (3′-UTRs) of target mRNAs. 
Studies have shown that some ARE-containing mRNAs are 
stabilized by HuR, whereas are destabilized by TTP. For 
example, HuR can up-regulate TNF-induced IL-6 expres-
sion by stabilizing its mRNA in human pulmonary micro-
vascular endothelial cells, whereas TTP promotes IL-6 
mRNA degradation [64]. In addition, Tiedie et al. [65] 
demonstrated that translation of the TNF-precursor at the 
ER requires expression of the ARE-binding and -stabilizing 
factor HuR or the absence of the ARE-binding and 
-destabilizing factor TTP. Phosphorylation of TTP by MK2 
deceases its affinity to the ARE, inhibits its ability to re-
place HuR, and permits HuR-mediated initiation of transla-
tion of TNF mRNA. Activation of inflammatory pathways 
in the endothelium contributes to vascular diseases, includ-
ing sepsis and atherosclerosis. Cheng et al. [66] demon-
strated that HuR promoted endothelial activation by sup-
pressing expression of endothelial nitric oxide synthase. 
Moreover, HuR also promotes the stability of ICAM-1 and 
VCAM-1 and increases leukocyte-endothelial cell adhesion. 
Knockdown of HuR with small interfering RNA (siRNA) 
inhibited inflammatory responses in endothelial cells, in-
cluding ICAM-1 and VCAM-1 up-regulation, NF-κB 
phosphorylation, and adhesion of monocytes. Interestingly, 
tissue staining of the mouse aorta revealed increased HuR 
expression in the arch that is exposed to disturbed flow. 
These results suggest that HuR plays a critical role in in-
ducing inflammatory response of endothelial cells under 
mechanical and biochemical stresses. The microvascular 
angiogenic response to an inflammatory stimulus was 
markedly diminished in the macrophages from HuR 
knockout mice despite the equal levels of macrophage lo-
calization to those observed in littermate wild-type controls. 
Furthermore, blood flow recovery and ischemic muscle ne-
ovascularization after femoral artery ligation were impaired 
in the conditional macrophage-specific HuR knockout mice. 
These results demonstrate that dynamic effects on mRNA, 
mediated by the RNA-binding and RNA-stabilizing protein 
HuR, are required for macrophage production of angiogenic 
factors, which play critical roles in the neovascular re-
sponses to a variety of stimuli, including tissue ischemia 
[67]. In another in vitro study, stimulation of HASMCs with 
LPS significantly increased the cytosolic HuR level in vitro. 
Systemic inflammation induced by LPS caused intimal hy-
perplasia and increased TLR4 and HuR expression. Further 
studies demonstrated that HuR can increase TLR4 mRNA 
stability by binding to its 3′UTR, which is correlated with 
the increased vascular smooth muscle proliferation. These 
results suggest that HuR contributes to regulation of 
hVSMC growth and homeostasis in pathologies associated 
with vascular smooth muscle proliferation [68]. Taken to-
gether, HuR is emerging as an important regulator in vas-
cular biology by targeting either vascular endothelial in-
flammation, or VSMC proliferation or macrophage activa-
tion. It may significantly contribute to the pathogenesis of 
vascular inflammatory diseases such as sepsis-induced or-
gan injury and atherosclerosis-associated diseases. 
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3.3  MCPIP1 
MCP-induced protein 1 (MCPIP1), also known as Regnase-1 
orZc3h12a, was identified as a novel protein harboring a 
CCCH-type zinc-finger domain and a PIN-like RNase do-
main [69,70]. MCPIP1 mRNA expression is induced by 
Toll-like receptor (TLR) ligands, interleukin (IL)-1β and 
various stress stimuli [7174]. MCPIP1 functions as an im-
portant negative regulator in both adaptive and innate im-
mune response through destabilizing mRNAs encoding 
immune related proteins including IL-6, IL-2 and IL-12p40 
via their 3′ untranslated regions [71,72,75]. As a conse-
quence, Mcpip1-deficient mice developed severe systemic 
inflammation, characterized by growth retardation, spleno-
megaly, lymphadenopathy, severe anemia and premature 
death [71,76]. In addition, the serum levels of proinflam-
matory cytokine and production of autoantibodies are also 
dramatically increased in Mcpip1-deficient mice [77]. 
MCPIP1 was firstly identified as an endogenous inhibitor in 
macrophage-induced inflammation. Under normal condition, 
MCPIP1 protein is highly enriched in the mouse lung, 
spleen, thymus, colon and intestine. MCPIP1 expression 
was significantly induced in macrophages by bacterium and 
virus infection and by endogenous cytokines such as TNFα 
and IL-1β. Overexpression of MCPIP1 in macrophages sig-
nificantly suppressed the proinflammatory cytokine produc-
tion such as IL-6 and IL-12. In the Mcpip1-deficient mac-
rophages, the expression of IL-6 was increased as its mRNA 
decay was impaired [71,72]. Besides macrophages, our pre-
vious studies also showed that MCPIP1 expression is 
up-regulated in the endothelial cells and VSMCs in the ad-
vanced atherosclerotic lesions. In culturing human umbilical 
vein endothelial cells (HUVECs), MCPIP1 expression was 
significantly induced by inflammatory cytokines TNFα and 
IL-1β and overexpression of MCPIP1 suppresses cyto-
kine-induced expression of VCAM-1, as well as monocyte 
adhesion to human ECs [78]. These studies demonstrated 
MCPIP1 as a feedback control of cytokine-induced endo-
thelial inflammation and suggest that MCPIP1 may be a 
critical regulator in vascular diseases such as sepsis and 
atherosclerosis. Indeed, Mcpip1-deficient mice are ex-
tremely sensitive to LPS-induced septic shock [79]. Espe-
cially, a minimum LPS challenge can cause severe inflam-
matory lung and liver injury and death in Mcpip1-deficient 
mice, suggesting that Mcpip1 may play an important role in 
maintaining the vascular homeostasis under severe bacte-
rium and virus infection. Activator of MCPIP1 enzymatic 
action may have therapeutic benefits for the patients with 
sepsis, severe viral infection and atherosclerosis-associated 
diseases. Besides MCPIP1, the other member in MCPIP1 
protein family Zc3h12c (also known as MCPIP3) also sig-
nificantly inhibited the endothelial cell inflammatory re-
sponse in vitro. Overexpression of Zc3h12c significantly 
attenuated TNFα-induced expression of chemokines and 
adhesive molecules, and thus reduced monocyte adherence 
to HUVECs. Conversely, siRNA-mediated knockdown of 
Zc3h12c increased the TNFα-induced expression of chemo-
kines and adhesive molecules in HUVECs. Furthermore, 
forced expression of Zc3h12c decreased TNFα-induced 
IKKα/β (IκB (inhibitor of nuclear factor κB) kinase α/β), 
IκBα phosphorylation and p65 nuclear translocation, sug-
gesting that Zc3h12c exerted its anti-inflammatory function 
probably by suppressing the NF-κB (nuclear factor κB) 
pathway. Thus Zc3h12c is also an endogenous inhibitor of 
TNFα-induced inflammatory signaling in HUVECs and 
might be a therapeutic target in vascular inflammatory dis-
eases [80]. How does MCPIP1 selectively target some spe-
cific mRNAs? Structural and biochemical analysis demon-
strated that MCPIP1 contains a PIN-like RNase domain and 
can directly degrade mRNA in vitro [81]. In the cells, 
MCPIP1 is predominantly localized in cytoplasm as small 
granule-like pattern. We have found that MCPIP1 is 
co-localized with GW-182 and Ago-2, which are major 
components of miRNA-mediated RNA silencing complex 
[82], suggesting that MCPIP1 may be involved in the 
miRNA-effector pathway. Further studies are needed to 
clarify this mechanism. Interestingly, Suzuki et al. [83] re-
ported that MCPIP1 can specifically recognize the terminal 
loops of precursors miRNAs and suppress miRNA biosyn-
thesis, suggesting that MCPIP1 may affect cell behavior by 
influencing the miRNA generation. 
3.4  Drosha and DGCR8 
microRNAs (miRNAs) represent a family of conserved 
short (≈22 nt) noncoding single-strand RNAs that have 
been identified in plants and animals. They are generated by 
the sequential processing of the RNA template by the en-
zyme Drosha and Dicer, and mature miRNAs can regulate 
the levels of gene expression at the posttranscriptional level. 
microRNAs participate in a diverse range of regulatory 
events via regulation of genes involved in the control of 
process such as development, differentiation, homeostasis, 
metabolism, growth, proliferation, and apoptosis [911]. 
microRNAs are highly expressed in endothelial cells and 
they regulate various aspects of vascular endothelial biology, 
which have been extensively reviewed elsewhere [1215]. 
In this review, we focus on the miRNA biogenesis enzyme 
Drosha and Dicer as well as RNA-binding protein DGCR8. 
They not only function through generation of miRNAs but 
also function independently of miRNAs. Drosha cleaves 
double-stranded primary miRNA by interacting with dou-
ble-stranded RNA binding protein DGCR8 and processes 
primary miRNA into precursor miRNA to participate in the 
miRNA biogenesis pathway. Fan et al. [84] found that dis-
ruption of Drosha in VSMCs resulted in embryonic lethality 
at E14.5 with severe liver hemorrhage in mutant embryos. 
The vascular structure was absent in the yolk sac of Drosha 
homozygotes at E14.5. Loss of Drosha reduced VSMC pro-
liferation in vitro and in vivo. The VSMC differentiation 
marker genes, including αSMA, SM22, and CNN1, and 
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endothelial cell marker CD31 were significantly down-  
regulated in Drosha conditional knockout (CKO) mice 
compared to controls. ERK1/2 mitogen-activated protein 
kinase and the phosphatidylinositol 3-kinase/AKT were 
attenuated in VSMCs in vitro and in vivo. These data 
demonstrated that Drosha is required for VSMC survival by 
targeting multiple signaling pathways [84]. Consistently, 
Chen et al. [85] also found that loss of DGCR8 in VSMCs 
resulted in extensive liver hemorrhage and embryonic mor-
tality between embryonic days (E) 12.5 and E13.5. DGCR8 
CKO embryos displayed dilated blood vessels and disar-
rayed vascular architecture. Blood vessels were absent in 
the yolk sac ofDGCR8 KOs after E12.5. Disruption of 
DGCR8 in VSMCs reduced VSMC proliferation and pro-
moted apoptosis in vitro and in vivo. In DGCR8 CKO em-
bryos and knockout VSMCs, differentiation marker genes, 
including αSMA, SM22, and CNN1, were significantly 
down-regulated, and the survival pathways of ERK1/2 mi-
togen-activated protein kinase and the phosphatidylinositol 
3-kinase/AKT were attenuated. The mechanisms that cause 
these phenotypes are not completely clear. Knockout of 
DGCR8 in VSMCs has led to down-regulation of the 
miR-17/92 and miR-143/145 clusters, suggesting that the 
misprocessing of miRNA maturation may contribute to the 
abnormal differentiation and proliferation of VSMCs [85]. 
Pan et al. [86] also reported that conditionally deleted the 
miRNA-processing enzyme Dicer in the proepicardium us-
ing Gata5-Cre mice leads to impaired epicardial epitheli-
al-to-mesenchymal transition and reduction in epicardial 
cell proliferation and differentiation into coronary smooth 
muscle cells. 
3.5  Argonaute 2 
Argonaute 2 (Ago2) is a central component of RNA-   
induced silencing complex and plays a key role in RNA 
interference and miRNA effector pathway. Ago2 is ex-
pressed in vascular endothelial cells and may play an essen-
tial role in regulation of endothelial dysfunction in miR-
NA-dependent mechanisms. In addition, some reported that 
Ago2, as a RNA binding protein, may function in a miR-
NA-independent way. Asai et al. [87] reported that knock-
ing down of Ago2 significantly suppressed VEGF- induced 
angiogenesis, which suggests that Ago2 is required for an-
giogenesis. Endothelial cell migration induced in response 
to VEGF is a crucial step of angiogenesis and it is depend-
ent on the activation of the p38 MAP-kinase pathway 
downstream of VEGFR2. Pin et al. [88] found that overex-
pression of Ago2 impaired VEGF-induced p38 activation 
and endothelial cell migration. The role of Ago2 in endo-
thelial dysfunction needs to be further explored.  
3.6  Others 
The RNA-binding protein Quaking (QKI) is a member of 
the “STAR” (signal transduction and activation of RNA) 
family. Proteins in this family are characterized by the 
presence of RNA-binding motif, KH domains, as well as 
SH2 and SH3 domains and potential phosphorylation sites, 
suggesting that they function in signal transduction path-
ways [89]. It is well known that QKI plays an important role 
in the postnatal central nervous system during myelination. 
Recent studies suggest that it also plays an essential role in 
blood vessel development [90]. In addition, van der Veer et 
al. [91] observed that QKI is highly expressed in neointimal 
VSMCs of human coronary restenoticlesions and neointima 
hyperplasia of mice. Abrogation of QKI attenuated fi-
broproliferative properties of VSMC and potently induced 
contractile apparatus protein expression. Further studies 
indicate that QKI localizes to the spliceosome and regulates 
myocardin splicing. Similarly, RA301/Trabeta, a se-
quence-specific RNA-binding protein, has also been found 
highly expressed in coronary artery with intimal thickening, 
and atherosclerotic aorta. RA301/Trabeta seems to also reg-
ulate VSMC proliferation [92]. The roles of these 
RNA-binding proteins in vascular endothelial dysfunction 
need to be further explored. 
4  Conclusion and future direction 
Normal EC function is critical for all aspects of vascular  
Table 1  Overview of RNA-binding proteins and their function  
RNA-binding proteins Function Refs 
Tristetraprolin Inhibition of vascular inflammation by promoting mRNA degradation of inflammatory cytokines [3941,4247,55,56] 
HuR Promotion of endothelial activation by stabilizing the mRNAs of cytokines and adhesion molecules   [6163,66] 
MCPIP1 
Inhibition of vascular inflammation by degradation the mRNA of inflammatory cytokines and suppressing 
NF-B signaling [6974,78,79] 
Zc3h12c Inhibition of vascular inflammation by suppressing NF-B signaling [80] 
Drosha Required for VSMC survival [84] 
DGCR8 Required for VSMC differentiation and proliferation [85] 
Argonaute 2 Promotion of VEGF-induced angiogenesis [87] 
Quaking Promotion of fibroproliferative properties of VSMC [88] 
RA301/Trabeta Regulation of VSMC proliferation [89] 
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homeostasis, such as control of blood vessel development, 
growth and differentiation; control of leukocyte trafficking; 
control of vascular tone; control of vascular barrier; control 
of platelet function, coagulation and fibrinolysis. Vascular 
endothelial dysfunction is associated with many important 
diseases such as atherosclerosis-associated heart attack and 
stroke, diabetes, sepsis and septic shock, severe virus infec-
tion-caused organ injury. Understanding of the pathogenesis 
and molecular regulatory mechanisms will provide insights 
into development of new therapeutic approaches to cure 
these diseases. microRNAs represent a novel layer that con-
trols the gene expression at a post-transcriptional level and 
have emerged as important regulators in endothelial dys-
function. However, miRNAs do not function alone. mi-
croRNAs must get the jobs done by closely cooperating 
with RNA-binding proteins. Increasing evidences suggest 
that the RNA-binding proteins such as TTP, MCPIP1, HuR, 
Drosha, and DGCR8 act as important components in gene 
expression at post-transcriptional level in a miRNA-    
dependent and/or independent manner. Their roles in regu-
lation of vascular endothelial dysfunction are also charac-
terized in recent publications (Table 1). Further studies in 
vivo and translational to human diseased samples will be 
definitely needed.  
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